Information Provided By: 
Fly News Breaks for April 5, 2016
RDHL
Apr 5, 2016 | 08:42 EDT
Roth Capital analyst Scott Henry sees a continued 'positive momentum' at RedHill Biopharma, with progress toward a Rizaport partnership in Spain and promising proof-of-concept data for RHB-104 to treat multiple sclerosis. Although Henry does not view these as core assets, he believes that this progress validates the company's business model. The analyst reiterates a Buy rating and his $26 price target on the stock.
News For RDHL From the Last 2 Days
